ASTH

Astrana Health, Inc. (ASTH) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Astrana Health, Inc. is a physician-centric, technology-enabled healthcare management company operating through three segments: Care Partners, Care Delivery, and Care Enablement. The company manages care for approximately 1.55 million patients through a network of over 20,000 contracted physicians. A significant event impacting this period was the July 1, 2025, acquisition of certain assets of Prospect Medical Holdings, Inc. ("Prospect"), which expanded the provider network and revenue base.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased by 56% ($344.7 million) year-over-year. This was driven primarily by the Prospect acquisition, which contributed $300.2 million in revenue, and a 53% increase in capitation revenue due to enrollees transitioning to full risk.
• Profitability: Net income attributable to Astrana increased by 116% to $14.4 million. Adjusted EBITDA rose 82% to $66.3 million.
• Expenses: Cost of services increased 57% ($310.3 million), largely due to medical costs associated with the Prospect acquisition and increased participation in value-based care models. Interest expense surged 120% to $16.1 million due to higher debt levels financing the acquisition.
• Segment Performance:
  • Care Partners: Revenue up 51% to $909.7 million; Operating income decreased 11% to $39.5 million due to higher cost of services growth.
  • Care Delivery: Revenue up 155% to $85.1 million; Operating loss narrowed slightly to $3.0 million.
  • Care Enablement: Revenue up 122% to $87.7 million; Operating income increased 470% to $20.2 million.

Guidance, Outlook, and Risks

• Regulatory Outlook: Management views the April 2026 CMS final 2027 Medicare Advantage payment rates positively, citing modest rate increases and stability in the risk adjustment model.
• Liquidity: The company maintains strong liquidity with $478.4 million in cash and $138.0 million remaining available under its revolving credit facility. Management believes it has sufficient liquidity for the next 12 months.
• Internal Controls: The company disclosed a material weakness in internal control over financial reporting related to the accounting for business combinations. This weakness was not remediated as of March 31, 2026, rendering disclosure controls and procedures ineffective. Remediation is ongoing.
• Legal Proceedings: A significant arbitration with a provider (CFC HP Provider) was settled in February 2026. The company paid $13.0 million in total ($12.0 million in late 2025 and $1.0 million in January 2026) and is seeking reimbursement from escrow funds established during the AHMS acquisition.

Investor Verification Checklist

• Remediation Progress: Verify the specific steps and timeline management is taking to remediate the material weakness in internal controls regarding business combinations.
• Prospect Integration: Assess the ongoing integration costs and the realization of synergies from the Prospect acquisition, particularly regarding the increase in cost of services.
• Debt Servicing: Review the impact of the increased debt load ($1.04 billion) on future interest expenses and compliance with leverage covenants (max 5.00x until March 2027, then 4.50x).
• Escrow Recovery: Monitor the status of the claim for reimbursement of the $14.0 million settlement payment from the escrow account related to the CFC HP arbitration.
• Non-GAAP Reconciliations: Scrutinize the "Other, net" adjustments in the Adjusted EBITDA reconciliation, which included $10.7 million in Q1 2026 for allowances on receivables and integration costs.